培美曲塞治疗晚期复治的非小细胞肺癌的近期疗效观察

Clinical effi ciency of pemetrexed in the treatment of advanced retreated non-small cell lung cancer

背景与目的:培美曲塞是多靶点的抗代谢类药物,已被批准用于非小细胞肺癌的二线治疗。本研究旨在观察培美曲塞单药治疗晚期复治的非小细胞肺癌的近期疗效及毒副反应。方法:17例晚期复治的非小细胞肺癌患者接受培美曲塞500mg/m2化疗,21d为1个周期,重复直至疾病进展或出现不可耐受的毒副作用。结果:总有效率(CR+PR)为11.8%,临床获益率(CR+PR+SD)为76.5%。主要毒副反应为骨髓抑制。结论:培美曲塞治疗晚期复治的非小细胞肺癌取得较明显的临床获益率,且毒副反应可耐受。

Background and purpose： Pemetrexed is a multitargeted anti-metabolite. Pemetrexed has been approved as the second-line treatment in non-small cell lung cancer. Our aim was to evaluate the clinical efficiency and toxicity of pemetrexed in treatment of advanced retreated non-small cell lung cancer. Methods： 17 advanced retreated NSCLC patients received pemetrexed at a dose of 500 mg/m^2, the chemotherapy was repeated every 21 days on two cycles until progressive disease or untolerant adverse effects. Results： Among 17 patients, the overall response rate was 11.8%, the clinical benefit rate was 76.5%, and the main toxicity was hematological toxicties. Conclusions： Pemetrexed is effective in treatment of advanced retreated non-small lung cancer and the toxicity can be well tolerated.